All fact checks
AI analysis
Fact check
“The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria.”
UnverifiableConfidence: LOW
Reasoning
The claim concerns whether the FD&C Act authorizes FDA to award priority review vouchers for rare pediatric disease products. Without any provided documents or citations, there is no basis to verify the statement.
On confidence: No evidence was supplied to confirm or refute the claim.
Evidence
No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.
Limitations
The assessment is limited to the absence of supplied evidence; external sources were not consulted.
- Last verified:
- Oct 6, 2026, 4:10 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FAYUVI (rebisufligene etisparvovec-hopf)Federal Register · Drug Administration, Human Services Department, Food, Health